1. Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131.
2. AWMSG, 2014. Sativex Preliminary Appraisal Recommendation. Available from: http://www.awmsg.org/awmsgonline/app/appraisalinfo/644.
Accessed August 2014.